Navigation Links
Arcturus Therapeutics Announces the Appointment of Drew Weissman M.D., Ph.D. to the Scientific Advisory Board
Date:11/3/2015

SAN DIEGO, Nov 3, 2015 /PRNewswire/ -- Arcturus Therapeutics Inc., a leading RNA medicines company, today announced the appointment of Drew Weissman, M.D, Ph.D. to its Scientific Advisory Board.   

Dr. Weissman, is a professor of Medicine at the Perelman School of Medicine, University of Pennsylvania with over 100 publications and patents. He received his graduate degrees from Boston University School of Medicine. Dr. Weissman co-discovered the ability of modified nucleosides in RNA to suppress activation of innate immune sensors and increase the translation of messenger RNA (mRNA).

Dr. Weissman's laboratory focuses on the study of RNA and innate immune system biology and the application of these findings to vaccine research, protein therapeutics, and gene therapy. His laboratory is currently developing new vaccine platforms, therapeutic proteins, and gene editing systems using nucleoside modified RNAs. He is also an Attending Physician at the Philadelphia Veterans Administration Medical Center, a member of The American Association of Immunologists, and a member of the American Federation for Clinical Research.

"We are delighted to add Dr. Weissman to our Scientific Advisory Board, as he brings new insights into the design of mRNA therapeutics", said Pad Chivukula, Ph.D., Chief Scientific Officer of Arcturus Therapeutics. "Dr. Weissman is a thought leader in the field of messenger RNA and his seminal discovery of the identification of modified nucleosides to prevent immunogenicity has led to a renaissance in the field of mRNA therapeutics."

Dr. Weissman stated, "I look forward with anticipation to work with Arcturus' UNA oligomer™ and LUNAR™ delivery technologies, as we identify effective therapeutics," and added, "Arcturus is leading the way in bringing safe and efficacious messenger RNA medicines to patients."

About Arcturus

Founded in 2013 and based in San Diego, Arcturus Therapeutics, Inc. is an RNA medicines company with enabling technologies – UNA Oligomer™ chemistry and LUNAR™ nanoparticle delivery. Arcturus' versatile RNA therapeutics platform can be applied toward all types of RNA medicines including small interfering RNA, messenger RNA, antisense RNA, microRNA and gene editing therapeutics.  The company owns unlocked nucleomonomer agent (UNA) technology including UNA Oligomers™, which are covered by its patent portfolio (34 patents and patent applications, issued in the U.S. and other countries).  Arcturus' proprietary UNA technology can be used to target any gene in the human genome, as well as viral genes, and other species for therapeutic purposes. For more information, visit www.ArcturusRx.com.

Logo - http://photos.prnewswire.com/prnh/20130531/MM24393LOGO

 

 

 


'/>"/>
SOURCE Arcturus Therapeutics Inc.
Copyright©2015 PR Newswire.
All rights reserved


Related medicine technology :

1. Arcturus Therapeutics Announces Strategic Collaboration with Johnson & Johnson Innovation to Discover and Develop RNA Medicines for Defined Indications
2. Arcturus Therapeutics to Present at the Genetic Rx Boston Biotech Conference
3. Arcturus Therapeutics to Present at the 26th Annual Piper Jaffray Healthcare Conference
4. Arcturus Therapeutics, Inc. Announces an RNAi Therapeutic Targeting Transthyretin-mediated Amyloidosis as its Flagship Program
5. Arcturus Therapeutics Acquires Cutting-Edge UNA Patent Estate from Marina Biotech
6. Aurigene to Present its CDK7, Dual PD-1/VISTA and IRAK4 Inhibitor Programs at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (November 5-9, Boston, MA)
7. Mast Therapeutics Announces Appointment Of Matthew Pauls To Board Of Directors
8. Georgia Erbez Appointed Chief Financial Officer Of Asterias Biotherapeutics
9. Aratana Therapeutics to Report Third Quarter Results
10. Mast Therapeutics To Host Third Quarter 2015 Financial Results And Corporate Update Conference Call
11. Shape Memory Therapeutics Hires Industry Veteran Ted Ruppel as CEO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/13/2020)... MATEO, Calif. (PRWEB) , ... February 13, 2020 , ... ... their finances show that they are maintaining a generally positive outlook on the ... contradictory indicators. , Asked if they are better off today than a year ago, ...
(Date:2/11/2020)... Calif. (PRWEB) , ... February 11, 2020 , ... ... in first aid and other safety measures, is offering courses for hospital and ... training is a requirement for medical practitioners like nurses, doctors, and other staff ...
(Date:2/11/2020)... , ... February 11, 2020 , ... Acuity Eye ... Eye Center run by Dr. Daniel Coden, Dr. Arthur Perry, and Dr. Steven Pratt ... have served patients in the La Jolla and San Diego community for over 40 ...
Breaking Medicine Technology:
(Date:2/10/2020)... , ... February 11, 2020 , ... R3 Medical Training ... March 11-12th, 2020 in Las Vegas. The training consists of thread lift placement on ... to register. , PDO thread lifts represent an excellent alternative currently for nonoperative facelift. ...
(Date:2/10/2020)... ... February 10, 2020 , ... ... Epidemiology Practice, has been elected president of the Society for Health Communication ... her team develop and implement award-winning, research-driven Federal social marketing campaigns and health ...
(Date:2/10/2020)... SANTA BARBARA, Calif. (PRWEB) , ... ... ... Palette Life Sciences, Inc., a medical device company dedicated to assisting ... conditions and diseases, today announced the launch of the Solesta® Reimbursement Assistance ...
(Date:2/10/2020)... ... February 10, 2020 , ... American Family Care (AFC), the ... expanding its healthcare network across New England. The first phase includes the ... fast-growing healthcare system. , AFC’s Founder and CEO, Dr. Bruce Irwin , pioneered ...
(Date:2/9/2020)... , ... February 09, 2020 , ... ... Neuropsychology and Psychology of Criminal Behavior at the University of Denver. Since 2013, ... screenings on individuals in county jails and have determined that 50-80% of the ...
Breaking Medicine News(10 mins):